Philips and Diagnostics Development win European Union 'Horizon Prize - Better Use of Antibiotics'

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a leader in HealthTech, and Diagnostics Development, a P&M Venge company spin-off from Uppsala University (Sweden), have demonstrated a proof-of-concept for the rapid and reliable detection of bacterial infection. The test is based on Philips' Minicare I-20 handheld diagnostics platform and detects the human neutrophil lipocalin (HNL) biomarker in a single 'finger-prick' drop of blood. In recognition of the test's ability to distinguish between acute bacterial and viral infections, and thereby mitigate the unnecessary use of antibiotics, the two companies were awarded the European Union 'Horizon Prize - Better Use of Antibiotics' during a special award ceremony on the evening of February 6, 2017.

Antimicrobial agents - such as antibiotics - have dramatically reduced the number of deaths from infectious diseases since their introduction 70 years ago. However, through their overuse and misuse, many micro-organisms have become resistant to them. It is estimated that each year this growing antimicrobial resistance (AMR) causes around 25,000 deaths and accounts for over EUR 1.5 billion in healthcare costs and productivity losses in Europe alone, making it one of the greatest challenges facing society today. To boost development and bring new and innovative players to AMR research, the EU issued a prize for the individual or team that most effectively meets the following challenge: "to develop a rapid test that will allow healthcare providers to distinguish at the point of care between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without antibiotics".

"This prize is a great recognition of how collaboration can lead to innovative diagnostic solutions that improve patient care," said Marcel van Kasteel, CEO of Handheld Diagnostics at Philips. "The HNL program for detection of bacterial infections perfectly fits with our 'open platform' strategy of bringing innovative biomarker content onto the Minicare I-20 platform in order to offer healthcare professionals a panel of relevant tests for acute settings. Activities are ongoing to further develop the HNL test for eventual implementation in routine clinical practice.

"In various studies, HNL has demonstrated superior performance compared to biomarkers currently used to diagnose bacterial infection," said Per Venge, CEO of P&M Venge AB. "I am therefore very excited that we have been able to successfully demonstrate the detection of HNL on the Minicare I-20 using blood samples from patients with upper respiratory tract infections in the Uppsala University hospital, where within a few minutes patients with a bacterial infection could clearly be distinguished from those with viral infections or other conditions."

Based on Philips' proprietary biosensor technology, the Minicare I-20 handheld diagnostics platform is designed to detect multiple target molecules at very low concentrations in a single 'finger-prick' blood sample, and display the results on a handheld analyzer within minutes. Philips already has CE marking for its Minicare I-20 based cardiac troponin I (cTnI) blood test for the rapid point-of-care diagnosis of heart attack, and it is currently developing further tests for acute care settings.

Minicare I-20 is simple and easy to use by non-laboratory staff. The analyzer's built-in connectivity allows direct transfer of the data to laboratory and hospital information systems to update patient files, while integrated calibration and fail-safe functionalities ensure the robustness and accuracy needed for confident on-the-spot decision making.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries.

Most Popular Now

AI could Improve Heart Attack Diagnosis …

An algorithm developed using artificial intelligence (AI) could soon be used by doctors to diagnose heart attacks with better speed and accuracy than ever before, according to new research from...

New Algorithm can Predict Diabetic Kidne…

Researchers from Sanford Burnham Prebys and the Chinese University of Hong Kong have developed a computational approach to predict whether a person with type 2 diabetes will develop kidney disease...

AI Predicts Future Pancreatic Cancer

An artificial intelligence (AI) tool has successfully identified people at the highest risk for pancreatic cancer up to three years before diagnosis using solely the patients’ medical records, according to...

AI Voice Coach Shows Promise in Depressi…

Artificial intelligence (AI) could be a useful tool in mental health treatment, according to the results of a new pilot study led by University of Illinois Chicago researchers. The study...

ChatGPT Passes Radiology Board Exam

The latest version of ChatGPT passed a radiology board-style exam, highlighting the potential of large language models but also revealing limitations that hinder reliability, according to two new research studies...

Scientists develop AI tool to predict Pa…

Scientists from UNSW Sydney with collaborators at Boston University have developed a tool that shows early promise in detecting Parkinson’s disease years before the first symptoms start appearing. In research published...

Better than Humans: AI in Intensive Care…

In the future, artificial intelligence (AI) will play an important role in medicine. In diagnostics, successful tests have already been performed: for example, the computer can learn to categorise images...

Could Online Gaming Social Networks Have…

For millions of Americans playing some type of video game is a daily occurrence. Games can be a welcome form of entertainment and relaxation for many, and the internet can...

Siemens Healthineers Opens State-of-the-…

Siemens Healthineers has opened its new Education & Development Center (EDC) in Erlangen. The open-plan building offers space for the currently 240 trainees and integrated degree program participants in Erlangen...

Siemens Healthineers Invests 80 Million …

Siemens Healthineers is building a new factory in Forchheim for the cultivation of crystals for semiconductor production. The total investment amounts to 80 million euros. The new factory is expected...

Orion Health Welcomes New Sales Director…

Orion Health has appointed a new sales director for Scotland. Gabriel Radford, who has a background in business development for companies working with health, social care, and local government, will...

AI Tool Outperforms Human Emergency Call…

A team of researchers from Denmark have developed a new artificial intelligence (AI) framework to address the number of strokes that go unrecognised by human emergency call handlers.(1) The framework...